Onco Actu du 29 novembre 2016

	1. Biologie
New ways to measure solid stress in tumors could lead to improved understanding, therapies [Mass General Hospital] Using these methods to make measurements in mouse models of both primary and metastatic tumors, as well as in a few human tumor samples, revealed that solid stress and stored elastic energy may be different in primary and metastatic tumors, since they depend on both tumor cells and the surrounding microenvironment.
Largest resource of human protein-protein interactions can help interpret genomic data [Mass General Hospital] Lage’s team, in collaboration with researchers in Denmark and the U.K., developed a computational framework to integrate data from more than 43,000 published articles, including data from eight established protein-protein interaction databases.
	3.4 Chimioprévention
Breast cancer drug that costs just 4p could save lives of women at high risk of the disease [The Telegraph] Nice estimates that around 622,970 women would be eligible to be offered anastrozole by their doctors. It is thought that the new recommendation could save around 39,000 women over the age of 50 from the disease.
	4. Dépistage, diagnostic et pronostic
In highly lethal type of leukemia, cancer gene predicts treatment response [Wash U in St. Louis] Patients whose cancer cells carry TP53 mutations respond to milder chemotherapy.
	5.2 Pharma
Chugai licenses out early-stage cancer candidate to Menarini [FierceBiotech] Japanese biopharma Chugai, majority owned by Roche, has licensed out an early oncology prospect to Italy’s Menarini Group. The deal will see a subsidiary of Menarini, the cancer-focused biotech known as Berlin-Chemie Menarini, get its hands on PA799, a class I PI3K inhibitor.
Formatting failings set to delay FDA ruling on cancer drug [FierceBiotech] Saint-Genis-Pouilly, France-based AAA learnt last week that the formatting problems are preventing FDA reviewers from analyzing the clinical trial data it filed to support approval of Lu-177-labeled somatostatin analogue peptide Lutathera.
	6.10.1 Politiques (USA)
21st Century Cures bill would weaken requirements for disclosing industry ties [STAT] “Major medical associations have lobbied relentlessly to hide the fact that physicians get pricey textbooks and other educational gifts from drug companies,” said Daniel Carlat, who runs a company that publishes CME newsletters for mental health practitioners.
21st Century Cures would require pharma to post policies on experimental drugs [STAT] The legislation would require drug makers to provide procedures and contact information for making requests, the general criteria a company will consider or use to approve requests, and the length of time anticipated to acknowledge a request has been received.
Elizabeth Warren rips 21st Century Cures bill and vows to fight it [STAT] While Warren said she supported many of the provisions, she called others “huge giveaways” to the drug industry. Warren cited several measures she viewed as especially outrageous, although she said she had countless more.
Regulatory Explainer: 21st Century Cures Redux and What it Will Mean for FDA [RAPS] The 996-page bill includes major tweaks to the way in which the US Food and Drug Administration (FDA) regulates drugs, devices and biologics, while providing the agency with $500 million over 10 years to implement provisions that seek to move such products to patients more quickly, while maintaining the same standard for safety and effectiveness that the agency has adhered to in the past.
ASCO Urges Members of Congress to Vote “Yes” on the 21st Century Cures Act [ASCO] ASCO has been a strong supporter of the legislation, and weighed in heavily throughout the legislative process to provide guidance and support key provisions of the bill.
House lines up biotech lollipops as support grows for an epic 21st Century Cures Act [EndPoints] According to Kaiser Health News, more than 1,400 lobbyists have taken a crack — for and against — various sections of this bill. And that helps explain why this compromise bill weighs in at an epic 944 pages.
	6.7 DMP, Big Data & applis
Big Data Coming In Faster Than Biomedical Researchers Can Process It [NPR] But, unlike the data scientists at Google and Facebook, medical researchers have done almost nothing as yet to systematically analyze the information in these records, Butte said. "As a country, I think we're investing close to zero analyzing any of that data," he said.
	6.7.1 Bioinformatique
For bigger data, more storage [Harvard Gazette] "This is the new normal. People are pulling genomic data sets wider and deeper than they’ve ever been,” said James Cuff, Harvard’s assistant dean and distinguished engineer for research computing.
	6.9 Controverses
‘It’s your fault you got cancer’: the blame game that doesn’t help anyone [The Conversation] These unequal degrees of compassion need to be adjusted to support people regardless of how well understood or visible their illness is. The idea of certain cancers being a person’s responsibility undermines the need to provide support and care to all those living with the disease.
NHS patients told to lose weight and quit smoking or face operation delays [The Guardian] NHS England approves plans from a Yorkshire health authority to restrict access to routine procedures.